CEO and Board Director
Scioto Biosciences
Scioto develops an Activated Bacterial Therapeutics platform that enhances the delivery and efficacy of live bacterial therapeutics by leveraging biofilm formation to optimize gut health. Their technology specifically targets gastrointestinal disorders and autism spectrum disorder, addressing unmet medical needs through improved therapeutic interactions within the gut-brain axis.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$15.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current live bacterial therapeutics (LBTs) often struggle to effectively colonize and persist within the gastrointestinal (GI) tract, limiting their therapeutic impact. This poor colonization hinders the potential of LBTs to address GI disorders and influence the gut-brain axis.
Solution
Scioto Biosciences is developing Activated Bacterial Therapeutics (ABT), a platform designed to enhance the delivery and efficacy of LBTs. The ABT platform leverages the natural ability of beneficial bacteria to form biofilms, which improves their activity and persistence within the GI tract. By optimizing microbiome delivery, Scioto aims to improve therapeutic interactions within the intestinal mucosa and realize the potential of the gut-brain axis to benefit individuals with autism and GI disorders. The activated bacteria are capable of persisting in the gut and are primed for interaction within the intestinal mucosa.
Target Audience
The primary target audience includes children and adults with autism and gastrointestinal disorders who could benefit from improved microbiome delivery and enhanced LBT efficacy.
Features
- ABT platform leverages bacterial biofilm formation to enhance LBT delivery and persistence.
- Focus on activation of beneficial bacteria to advance healing in the GI tract.
- Targets unmet medical needs in gastrointestinal disorders and autism spectrum disorder.
- Completed Phase Ib study in patients with Autism Spectrum Disorder.